Boston Scientific Climbs
JP Morgan says Boston Scientific (BSX ) remains their leading near-term story on drug-eluting stents. The brokerage firm raised its estimates and continues to recommend the shares.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.